Professor Michael Hofman, a Nuclear Medicine Physician, leads the Peter Mac's PET/CT program, the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) and is a member of the Peter Mac Research Leadership Group.  He was named as Australia's top researcher in the field of Nuclear Medicine, Radiotherapy & Molecular Imaging ("The Australian" Top 250 Researchers) in 2024 and 2025. His groundbreaking research in PSMA PET and PSMA radioligand therapy has revolutionised prostate cancer imaging and treatment, resulting in FDA approval, Australian MBS funding, and a $2.1 billion investment by Novartis.

Michael’s passion for novel radiopharmaceuticals drives him to collaborate globally on Phase I, II, and III clinical trials, addressing unmet needs in oncology. As a key member of the Australasian Radiopharmaceutical Trials Network's scientific committee, he helped create a 10+ centre network across Australia, producing two landmark clinical trials published in The Lancet.

A highly sought-after speaker, Professor Hofman has given over 250 talks in 25+ countries at prominent conferences. His work has attracted more than $65 million in active grants, including a $15 million collaboration to develop next generation theranostics and $10 million grant from ACRF to install a first-in-the-world Total Body PET/CT at Peter Mac.

Professor Hofman has a leading academic track record for his specialty, with over 300 peer reviewed manuscripts and book chapters. He has received numerous awards including the 2024 Saul Hertz MD Award, ACTA Clinical Trial of the Year Award 2021, Society of Nuclear Medicine and Molecular Imaging (SNMMI) Image of the Year 2018 and awards for best scientific research at several international conferences. Elected memberships include Fellowship of the Society of Nuclear Medicine and Molecular Imaging (2024),Singapore Radiological Society (2024), the Australian Academy of Health and Medical Sciences (2023), Nuclear Society of Singapore (2023) and the International Cancer Imaging Society (2015). He was a member of the oncology subcommittee of the Australian MBS Review achieving expanded equitable access to PET funding in Australia.

Disclosures: Doctors often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organisations outside of Peter Mac, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. As a commitment to transparency, Prof. Hofman discloses the following relationships and financial interests:

• Professional services and activities (to Peter Mac): AdvanCell, Bayer, Isotopia, Novartis
• Professional services and activities (personal consulting fees for lectures or advisory board): Janssen, MSD, Sanofi
• Equity (personal): AdvanCell
• Grants (to Peter Mac): Prostate Cancer Foundation (PCF), Australian Research Cancer Foundation (ACRF),  Movember, Medical Research Future Fund (MRFF), National Health and Medical Research Council (NHMRC), Peter MacCallum Foundation.